Aligned with the needs of the growing and increasingly complex field of oncology, Advarra’s Central Oncology Review (COR) provides the robust human subject protections review that cancer research institutions expect.


COR’s IRB roster includes distinguished oncologists and individuals from leading cancer centers, including ASCO-member oncologists, as well as patient advocates. COR is experienced in reviewing specialized research protocols such as basket, umbrella, and targeted therapy trials.

Accelerated Startup

Advarra’s IRB members understand the latest oncology methodologies and discoveries, which reduces unnecessary follow-up during the review process. COR helps researchers meet study activation milestones more quickly and speed patient accrual.


COR acts as an extension of internal research programs, providing expertise and support to help institutions navigate the latest developments in oncology research, gene therapy review, and single IRB mandates. We have served as the IRB of record for 80% of all NCI-designated cancer centers.


COR maintains a transparent review process, offering access to documents and data in real time with the added ability to discuss issues with a dedicated support specialist. Always know the study’s review status, anytime, anywhere.

IRB Experience in Oncology

  • Antibody-drug conjugates
  • Bladder/urinary tract cancer
  • Blood and lymph cancers
  • Breast cancer
  • Cancer diagnostics
  • Cervical cancer
  • Chemotherapy
  • Colon/colorectal cancer
  • Endometrial cancer
  • Gastric cancer
  • Gene therapy
  • Head and neck cancer
  • Immunotherapy (such as CAR-T cell therapy)
  • Liver cancer
  • Lung cancer
  • Ovarian cancer
  • Pancreatic cancer
  • Palliative care management
  • Precision medicine (such as basket, umbrella, and targeted therapy trials)
  • Prostate cancer
  • Radiotherapy
  • Renal cancer
  • Sarcoma
  • Skin cancer

Ready for Solutions That Are Altogether Better?

Tell us what you’d like Advarra to do for your research program.